The effect of glucagon-like peptide 1 on cardiovascular risk

被引：0
|
作者：
Jacob Sivertsen
Jaya Rosenmeier
Jens J. Holst
Tina Vilsbøll
机构：
[1] Gentofte Hospital,Department of Cardiology
[2] University of Copenhagen,Diabetes Research Division, Department of Internal Medicine
[3] Gentofte Hospital,Department of Biomedical Sciences
[4] University of Copenhagen,undefined
[5] The NovoNordisk Foundation Center for Basic Metabolic Research,undefined
[6] The Panum Institute,undefined
[7] University of Copenhagen,undefined
来源：
Nature Reviews Cardiology | 2012年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Glucagon-like peptide 1 (GLP)-based therapies reduce blood glucose levels in patients with type 2 diabetes mellitus. Interestingly, GLP 1 receptor agonists can also have beneficial effects on cardiovascular risk. Dr. Sivertsen and colleagues provide an overview of the cardiovascular mechanisms targeted by GLP 1-based therapies and discuss clinical data for long-term management of cardiovascular risk in patients treated with these agents.
引用
收藏
页码：209 / 222
页数：13
相关论文
共 50 条
  • [21] Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
    Kang, Yu Mi
    Jung, Chang Hee
    ENDOCRINOLOGY AND METABOLISM, 2016, 31 (02) : 258 - 274
  • [22] Glucagon-like peptide-1 and cardiovascular system: pathophysiological mechanisms
    Avogaro, Angelo
    GIORNALE ITALIANO DI CARDIOLOGIA, 2010, 11 (12) : 18S - 25S
  • [23] Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
    Reed, Josh
    Kanamarlapudi, Venkateswarlu
    Bain, Stephen
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2018, 7 (01): : 18 - 23
  • [24] The physiology of glucagon-like peptide 1
    Holst, Jens Juul
    PHYSIOLOGICAL REVIEWS, 2007, 87 (04) : 1409 - 1439
  • [25] Glucagon-like peptide-1
    Doyle, ME
    Egan, JM
    RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 : 377 - 399
  • [26] Glucagon-like peptide 1 and appetite
    Dailey, Megan J.
    Moran, Timothy H.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2013, 24 (02): : 85 - 91
  • [27] The discovery of glucagon-like peptide 1
    Lund, PK
    REGULATORY PEPTIDES, 2005, 128 (02) : 93 - 96
  • [28] Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
    Song, Rui
    Qian, Hang
    Wang, Yunlian
    Li, Qingmei
    Li, Dongfeng
    Chen, Jishun
    Yang, Jingning
    Zhong, Jixin
    Yang, Handong
    Min, Xinwen
    Xu, Hao
    Yang, Yong
    Chen, Jun
    JOURNAL OF DIABETES RESEARCH, 2022, 2022
  • [29] The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis
    Maciel, Michel Garcia
    Soares Beserra, Bruna Teles
    Barroso Oliveira, Fernanda Cerqueira
    Ribeiro, Carolina Martins
    Coelho, Michella Soares
    Rocha Neves, Francisco de Assis
    Amato, Angelica Amorim
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 142 : 222 - 235
  • [30] Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1
    Watanabe, Ayahisa
    Nishijima, Ken-ichi
    Zhao, Songji
    Tanaka, Yoshikazu
    Itoh, Takeshi
    Takemoto, Hiroshi
    Tamaki, Nagara
    Kuge, Yuji
    ANNALS OF NUCLEAR MEDICINE, 2012, 26 (02) : 184 - 191
12345